Original language | English |
---|---|
Pages (from-to) | 92-92 |
Number of pages | 1 |
Journal | New England Journal of Medicine |
Volume | 382 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2 Jan 2020 |
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
V.B.C. Biemans*, F. Hoentjen, M.J. Pierik
*Corresponding author for this work
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review